Working… Menu

Pembrolizumab and EDP1503 in Advanced Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03595683
Recruitment Status : Recruiting
First Posted : July 23, 2018
Last Update Posted : November 14, 2018
Merck Sharp & Dohme Corp.
Evelo Biosciences
Information provided by (Responsible Party):
University of Chicago

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : November 2, 2021
Estimated Study Completion Date : November 2, 2023